Jerusalem Pharmaceuticals Co Ltd

The company maintains a strong liquidity position, with a current ratio of 3.41 and cash and equivalents of $12.2 million, indicating a robust ability to meet short-term obligations. The debt-to-equity ratio is 0.02, reflecting a conservative capital structure with minimal leverage. Free cash flow of $8.9 million supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity of 11.69% and a return on assets of 8.89%, both exceeding the typical thresholds for the pharmaceutical industry. The operating margin of 26.8% (calculated from operating income of $13.1 million on revenue of $48.9 million) is strong, suggesting efficient cost management and pricing power. Revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond Palestine. The company's exposure to local economic and political conditions may pose concentration risk, though no immediate liquidity or dilution flags were detected in filings. Growth trajectory is supported by a free cash flow of $8.9 million and a capital expenditure of -$2.1 million, indicating a focus on cost optimization rather than expansion. No specific growth initiatives were disclosed in recent filings, but the company's operating cash flow of $3.6 million supports ongoing operations. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce financial risk. No dilution pressure is expected in the near term, with shares outstanding remaining unchanged at 36 million for both basic and diluted shares. Recent filings and transcripts do not disclose material events or strategic shifts. The company's operations remain stable, with no significant changes in business strategy or capital structure reported in the latest available data.